X4 Pharmaceuticals, Inc. (XFOR)
After hours:
| Previous close | 1.1200 |
| Open | 1.1300 |
| Bid | 1.0600 x 300 |
| Ask | 1.1200 x 2200 |
| Day's range | 1.0700 - 1.1400 |
| 52-week range | 0.5720 - 2.5750 |
| Volume | |
| Avg. volume | 3,118,604 |
| Market cap | 185.571M |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. The decision is based on a late-stage study where the therapy showed 60% reduction in infection rate compared to placebo when tested in patients with WHIM syndrome.
- Simply Wall St.
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
Key Insights Institutions' substantial holdings in X4 Pharmaceuticals implies that they have significant influence over...
- Insider Monkey
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript March 21, 2024 X4 Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.15. XFOR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. And welcome to the X4 […]
